Fibroblast growth factor-19: Development, analytical characterization and clinical evaluation of a new ELISA test
Objective. Since fibroblast growth factor 19 (FGF-19) is a potent metabolic regulator that influences glucose and lipid homeostasis, our aim was to develop an ELISA assay for measuring FGF-19 in human serum and to investigate its concentrations in healthy volunteers and patients suffering from metab...
Gespeichert in:
| Veröffentlicht in: | Scandinavian journal of clinical and laboratory investigation 2008, Vol.68 (6), p.501-507 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 507 |
|---|---|
| container_issue | 6 |
| container_start_page | 501 |
| container_title | Scandinavian journal of clinical and laboratory investigation |
| container_volume | 68 |
| creator | Stejskal, D. Karpíšek, M. Hanulová, Z. Stejskal, P. |
| description | Objective. Since fibroblast growth factor 19 (FGF-19) is a potent metabolic regulator that influences glucose and lipid homeostasis, our aim was to develop an ELISA assay for measuring FGF-19 in human serum and to investigate its concentrations in healthy volunteers and patients suffering from metabolic syndrome. Material and methods. A sandwich ELISA method was developed for quantitative determination of human FGF-19 in serum samples. Blood pressure, waist circumference, FGF-21 serum levels, serum cholesterol, triacylglycerols, HDL-cholesterol, LDL-cholesterol, insulin, glucose, adiponectin, uric acid, creatinine, hs-CRP and calculated BMI and Quicki insulin sensitivity index were measured in 153 healthy volunteers and 66 persons with metabolic syndrome. Results. Neither sex nor age influenced FGF-19 serum concentration in the healthy volunteers. Probands with metabolic syndrome had 65 % lower FGF-19 serum values than the healthy ones (medians 158.6 versus 242.4 ng L; p |
| doi_str_mv | 10.1080/00365510701854967 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_18609104</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69611696</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-2237a4be3077588a347c5f4729aa578d7001ed45f0dd9116eba76082e544e4673</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhAdggr1iRYif-C7CpSlsqjcQCWEc3zg3jyomnttPR8PS4zEgIIXVlXZ_vHFvnEvKaszPODHvPWKOk5EwzbqRolX5CVlyyutLKqKdk9aBXBWhOyIuUblmZGyOekxNuFGs5Eytyd-X6GHoPKdOfMezyho5gc4gVbz_Qz3iPPmwnnPM7CjP4fXYWPLUbiIXC6H5BdmEu2kCtd_MfFe_BL4f7MFKgM-7o5frm2znNmPJL8mwEn_DV8TwlP64uv198qdZfr28uzteVFZrlqq4bDaLHhmktjYFGaCtHoesWQGozaMY4DkKObBhazhX2oBUzNUohUCjdnJK3h9xtDHdLebibXLLoPcwYltSpVhVbqwrID6CNIaWIY7eNboK47zjrHnru_uu5eN4cw5d-wuGv41hsAT4dADePIU6wC9EPXYa9D3GMMFuXuuax_I__2DcIPm8sROxuwxLLJtIjv_sNPCmdEw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69611696</pqid></control><display><type>article</type><title>Fibroblast growth factor-19: Development, analytical characterization and clinical evaluation of a new ELISA test</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Stejskal, D. ; Karpíšek, M. ; Hanulová, Z. ; Stejskal, P.</creator><creatorcontrib>Stejskal, D. ; Karpíšek, M. ; Hanulová, Z. ; Stejskal, P.</creatorcontrib><description>Objective. Since fibroblast growth factor 19 (FGF-19) is a potent metabolic regulator that influences glucose and lipid homeostasis, our aim was to develop an ELISA assay for measuring FGF-19 in human serum and to investigate its concentrations in healthy volunteers and patients suffering from metabolic syndrome. Material and methods. A sandwich ELISA method was developed for quantitative determination of human FGF-19 in serum samples. Blood pressure, waist circumference, FGF-21 serum levels, serum cholesterol, triacylglycerols, HDL-cholesterol, LDL-cholesterol, insulin, glucose, adiponectin, uric acid, creatinine, hs-CRP and calculated BMI and Quicki insulin sensitivity index were measured in 153 healthy volunteers and 66 persons with metabolic syndrome. Results. Neither sex nor age influenced FGF-19 serum concentration in the healthy volunteers. Probands with metabolic syndrome had 65 % lower FGF-19 serum values than the healthy ones (medians 158.6 versus 242.4 ng L; p<0.01). FGF-19 correlated with glucose (r = −0.35, p<0.01), HDL (r = 0.24, p = 0.045), triacylglycerols (r = −0.19, p = 0.05) and with a number of other risk facors for metabolic syndrome (r = −0.28, p = 0.01). When adjusted to the concentrations of triacylglycerols, BMI and glucose, and finally to all data pertinent to FGF-19 (according to correlation analysis), our data indicate that FGF-19 is an independent marker of metabolic syndrome. Conclusions. The present study demonstrates the analytical properties of the ELISA FGF-19 assay and its usefulness when studying the metabolic syndrome. Serum concentrations of FGF-19 could be new key predictors of metabolic syndrome and thereby even a new negative risk factor of atherosclerosis.</description><identifier>ISSN: 0036-5513</identifier><identifier>EISSN: 1502-7686</identifier><identifier>DOI: 10.1080/00365510701854967</identifier><identifier>PMID: 18609104</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Diabetes mellitus ; Diabetes Mellitus, Type 2 - blood ; ELISA ; Enzyme-Linked Immunosorbent Assay - methods ; Female ; FGF-19 ; Fibroblast Growth Factors - analysis ; glucose and lipid homeostasis ; Humans ; Male ; metabolic syndrome ; Metabolic Syndrome - blood ; Recombinant Proteins - analysis</subject><ispartof>Scandinavian journal of clinical and laboratory investigation, 2008, Vol.68 (6), p.501-507</ispartof><rights>2008 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-2237a4be3077588a347c5f4729aa578d7001ed45f0dd9116eba76082e544e4673</citedby><cites>FETCH-LOGICAL-c470t-2237a4be3077588a347c5f4729aa578d7001ed45f0dd9116eba76082e544e4673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/00365510701854967$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/00365510701854967$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,4010,27900,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18609104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stejskal, D.</creatorcontrib><creatorcontrib>Karpíšek, M.</creatorcontrib><creatorcontrib>Hanulová, Z.</creatorcontrib><creatorcontrib>Stejskal, P.</creatorcontrib><title>Fibroblast growth factor-19: Development, analytical characterization and clinical evaluation of a new ELISA test</title><title>Scandinavian journal of clinical and laboratory investigation</title><addtitle>Scand J Clin Lab Invest</addtitle><description>Objective. Since fibroblast growth factor 19 (FGF-19) is a potent metabolic regulator that influences glucose and lipid homeostasis, our aim was to develop an ELISA assay for measuring FGF-19 in human serum and to investigate its concentrations in healthy volunteers and patients suffering from metabolic syndrome. Material and methods. A sandwich ELISA method was developed for quantitative determination of human FGF-19 in serum samples. Blood pressure, waist circumference, FGF-21 serum levels, serum cholesterol, triacylglycerols, HDL-cholesterol, LDL-cholesterol, insulin, glucose, adiponectin, uric acid, creatinine, hs-CRP and calculated BMI and Quicki insulin sensitivity index were measured in 153 healthy volunteers and 66 persons with metabolic syndrome. Results. Neither sex nor age influenced FGF-19 serum concentration in the healthy volunteers. Probands with metabolic syndrome had 65 % lower FGF-19 serum values than the healthy ones (medians 158.6 versus 242.4 ng L; p<0.01). FGF-19 correlated with glucose (r = −0.35, p<0.01), HDL (r = 0.24, p = 0.045), triacylglycerols (r = −0.19, p = 0.05) and with a number of other risk facors for metabolic syndrome (r = −0.28, p = 0.01). When adjusted to the concentrations of triacylglycerols, BMI and glucose, and finally to all data pertinent to FGF-19 (according to correlation analysis), our data indicate that FGF-19 is an independent marker of metabolic syndrome. Conclusions. The present study demonstrates the analytical properties of the ELISA FGF-19 assay and its usefulness when studying the metabolic syndrome. Serum concentrations of FGF-19 could be new key predictors of metabolic syndrome and thereby even a new negative risk factor of atherosclerosis.</description><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>ELISA</subject><subject>Enzyme-Linked Immunosorbent Assay - methods</subject><subject>Female</subject><subject>FGF-19</subject><subject>Fibroblast Growth Factors - analysis</subject><subject>glucose and lipid homeostasis</subject><subject>Humans</subject><subject>Male</subject><subject>metabolic syndrome</subject><subject>Metabolic Syndrome - blood</subject><subject>Recombinant Proteins - analysis</subject><issn>0036-5513</issn><issn>1502-7686</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhS0EokPhAdggr1iRYif-C7CpSlsqjcQCWEc3zg3jyomnttPR8PS4zEgIIXVlXZ_vHFvnEvKaszPODHvPWKOk5EwzbqRolX5CVlyyutLKqKdk9aBXBWhOyIuUblmZGyOekxNuFGs5Eytyd-X6GHoPKdOfMezyho5gc4gVbz_Qz3iPPmwnnPM7CjP4fXYWPLUbiIXC6H5BdmEu2kCtd_MfFe_BL4f7MFKgM-7o5frm2znNmPJL8mwEn_DV8TwlP64uv198qdZfr28uzteVFZrlqq4bDaLHhmktjYFGaCtHoesWQGozaMY4DkKObBhazhX2oBUzNUohUCjdnJK3h9xtDHdLebibXLLoPcwYltSpVhVbqwrID6CNIaWIY7eNboK47zjrHnru_uu5eN4cw5d-wuGv41hsAT4dADePIU6wC9EPXYa9D3GMMFuXuuax_I__2DcIPm8sROxuwxLLJtIjv_sNPCmdEw</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>Stejskal, D.</creator><creator>Karpíšek, M.</creator><creator>Hanulová, Z.</creator><creator>Stejskal, P.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2008</creationdate><title>Fibroblast growth factor-19: Development, analytical characterization and clinical evaluation of a new ELISA test</title><author>Stejskal, D. ; Karpíšek, M. ; Hanulová, Z. ; Stejskal, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-2237a4be3077588a347c5f4729aa578d7001ed45f0dd9116eba76082e544e4673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>ELISA</topic><topic>Enzyme-Linked Immunosorbent Assay - methods</topic><topic>Female</topic><topic>FGF-19</topic><topic>Fibroblast Growth Factors - analysis</topic><topic>glucose and lipid homeostasis</topic><topic>Humans</topic><topic>Male</topic><topic>metabolic syndrome</topic><topic>Metabolic Syndrome - blood</topic><topic>Recombinant Proteins - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stejskal, D.</creatorcontrib><creatorcontrib>Karpíšek, M.</creatorcontrib><creatorcontrib>Hanulová, Z.</creatorcontrib><creatorcontrib>Stejskal, P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Scandinavian journal of clinical and laboratory investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stejskal, D.</au><au>Karpíšek, M.</au><au>Hanulová, Z.</au><au>Stejskal, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibroblast growth factor-19: Development, analytical characterization and clinical evaluation of a new ELISA test</atitle><jtitle>Scandinavian journal of clinical and laboratory investigation</jtitle><addtitle>Scand J Clin Lab Invest</addtitle><date>2008</date><risdate>2008</risdate><volume>68</volume><issue>6</issue><spage>501</spage><epage>507</epage><pages>501-507</pages><issn>0036-5513</issn><eissn>1502-7686</eissn><abstract>Objective. Since fibroblast growth factor 19 (FGF-19) is a potent metabolic regulator that influences glucose and lipid homeostasis, our aim was to develop an ELISA assay for measuring FGF-19 in human serum and to investigate its concentrations in healthy volunteers and patients suffering from metabolic syndrome. Material and methods. A sandwich ELISA method was developed for quantitative determination of human FGF-19 in serum samples. Blood pressure, waist circumference, FGF-21 serum levels, serum cholesterol, triacylglycerols, HDL-cholesterol, LDL-cholesterol, insulin, glucose, adiponectin, uric acid, creatinine, hs-CRP and calculated BMI and Quicki insulin sensitivity index were measured in 153 healthy volunteers and 66 persons with metabolic syndrome. Results. Neither sex nor age influenced FGF-19 serum concentration in the healthy volunteers. Probands with metabolic syndrome had 65 % lower FGF-19 serum values than the healthy ones (medians 158.6 versus 242.4 ng L; p<0.01). FGF-19 correlated with glucose (r = −0.35, p<0.01), HDL (r = 0.24, p = 0.045), triacylglycerols (r = −0.19, p = 0.05) and with a number of other risk facors for metabolic syndrome (r = −0.28, p = 0.01). When adjusted to the concentrations of triacylglycerols, BMI and glucose, and finally to all data pertinent to FGF-19 (according to correlation analysis), our data indicate that FGF-19 is an independent marker of metabolic syndrome. Conclusions. The present study demonstrates the analytical properties of the ELISA FGF-19 assay and its usefulness when studying the metabolic syndrome. Serum concentrations of FGF-19 could be new key predictors of metabolic syndrome and thereby even a new negative risk factor of atherosclerosis.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>18609104</pmid><doi>10.1080/00365510701854967</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0036-5513 |
| ispartof | Scandinavian journal of clinical and laboratory investigation, 2008, Vol.68 (6), p.501-507 |
| issn | 0036-5513 1502-7686 |
| language | eng |
| recordid | cdi_pubmed_primary_18609104 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Diabetes mellitus Diabetes Mellitus, Type 2 - blood ELISA Enzyme-Linked Immunosorbent Assay - methods Female FGF-19 Fibroblast Growth Factors - analysis glucose and lipid homeostasis Humans Male metabolic syndrome Metabolic Syndrome - blood Recombinant Proteins - analysis |
| title | Fibroblast growth factor-19: Development, analytical characterization and clinical evaluation of a new ELISA test |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A18%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibroblast%20growth%20factor-19:%20Development,%20analytical%20characterization%20and%20clinical%20evaluation%20of%20a%20new%20ELISA%20test&rft.jtitle=Scandinavian%20journal%20of%20clinical%20and%20laboratory%20investigation&rft.au=Stejskal,%20D.&rft.date=2008&rft.volume=68&rft.issue=6&rft.spage=501&rft.epage=507&rft.pages=501-507&rft.issn=0036-5513&rft.eissn=1502-7686&rft_id=info:doi/10.1080/00365510701854967&rft_dat=%3Cproquest_pubme%3E69611696%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69611696&rft_id=info:pmid/18609104&rfr_iscdi=true |